Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.51 |
| ▸ | HTR1A | P08908 | 6/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.42 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770007 | 0.92 | SLC6A2 (0.49) | DRD3HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL6770680 | 0.90 | MEN1 (0.48) | DRD3HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL6769621 | 0.89 | HTR1A (0.53) | DRD3HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL6771841 | 0.89 | DRD3 (0.46) | DRD3HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL7601341 | 0.89 | DRD3 (0.50) | DRD3HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL6771002 | 0.86 | HTR1A (0.49) | DRD3HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL6767367 | 0.85 | DRD3 (0.48) | DRD3HTR1AHTR2ADRD2DRD4 | |
| SCHEMBL6766415 | 0.85 | HTR1A (0.51) | DRD3HTR1AHTR2AHTR2CDRD2 | |
| SCHEMBL6766578 | 0.85 | HTR1A (0.51) | DRD3HTR1AHTR2ADRD2SLC6A4 | |
| SCHEMBL6770052 | 0.84 | HTR1A (0.52) | DRD3HTR1AHTR2AHTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821967-B2 | AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-11-23 | — | — | US | disclosed |
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | MTTP, CETP, CPT1A | DRD3 2928/4885HTR1A 1523/4885HTR2A 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.